2016
An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression
Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D, Schwartz MA. An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell 2016, 30: 432-443. PMID: 27593345, PMCID: PMC5154333, DOI: 10.1016/j.ccell.2016.08.002.Peer-Reviewed Original ResearchConceptsBladder cancer metastasisCancer metastasisLymph node metastasisPoor clinical outcomeTumor-associated macrophagesPrimary tumor growthPotential therapeutic targetOsteopontin expression correlatesNode metastasisClinical outcomesPrimary tumorCD44 axisTherapeutic targetTumor aggressivenessMetastasisTumor growthExpression correlatesTumor cellsRac-GEF Tiam1Osteopontin bindsMetastasis suppressionRac1 axisTumorsCD44RhoGDI2
2008
Integrin Agonists as Adjuvants in Chemotherapy for Melanoma
Schwartz MA, McRoberts K, Coyner M, Andarawewa KL, Frierson HF, Sanders JM, Swenson S, Markland F, Conaway MR, Theodorescu D. Integrin Agonists as Adjuvants in Chemotherapy for Melanoma. Clinical Cancer Research 2008, 14: 6193-6197. PMID: 18829498, DOI: 10.1158/1078-0432.ccr-08-1285.Peer-Reviewed Original ResearchConceptsMelanoma linesExtracellular matrixMetastatic melanomaM21 tumorsTherapeutic responseImmunodeficient miceTumor volumeChemotherapyClonal growth assaysTherapy resistanceTumor growthHuman melanomaChemotherapeutic efficacyMelanomaTumor cellsDrug 1Survival assaysM21 cellsM21 melanomaSmall nestsIntegrin agonistsIntegrin-dependent adhesionTumorsMiceSnake venom